Technology ID

High-Throughput COVID-19 Diagnostic Test that Detects Both Viral and Host Nucleic Acid

Lead Inventor
Lozoya, Oswaldo (NIEHS)
Papa, Brian (NIEHS)
Therapeutic Areas
Infectious Disease
Development Stages
Research Products
Research Equipment
The rapid worldwide spread and impact of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created a need for accurate, reliable, and readily accessible testing on a massive scale.

NIEHS researchers developed a massively paralleled multiplexed screening method using next generation sequencing (NGS). This method uses sample-specific barcoded indexes that detect both SARS-COV-2 virus and the host’s transcriptional response to infection simultaneously. By matching existing laboratory protocols for PCR-based sample processing, this assay is easily incorporated into existing CLIA-certified facilities. This testing approach provides the capability for testing tens of thousands of patient samples in a large bolus, allowing accurate and fast-turnaround SARS-CoV-2 testing capacity at population scale, and permits monitoring of at-risk individuals.
Commercial Applications
  • Diagnostic test for detecting infectious organisms, including SARS-CoV-2
Competitive Advantages
  • Reduction in reagents needed to perform a test, reducing test cost and bottleneck of critical reagents used during nucleic acid amplification
  • Simultaneously detect the pathogen and a host’s transcriptional response to infection by the pathogen
  • Gene expression information from the donor can be used to predict disease severity
Licensing Contact:
Choudhry, Vidita
Phone: 301-594-4095